{
    "clinical_study": {
        "@rank": "97641", 
        "acronym": "CARE-ROP", 
        "arm_group": [
            {
                "arm_group_label": "Ranibizumab 0.12 mg", 
                "arm_group_type": "Experimental", 
                "description": "20 \u00b5l of the 6 mg/ml ranibizumab concentration will be applied intravitreally. After an initial response the same dose as in the first injection can be re-applied after at least four weeks post injection.\nA maximum number of 3 regular re-injections can be applied."
            }, 
            {
                "arm_group_label": "Ranibizumab 0.20 mg", 
                "arm_group_type": "Experimental", 
                "description": "20 \u00b5l of the 10 mg/ml ranibizumab concentration will be applied intravitreally. After an initial response the same dose as in the first injection can be re-applied after at least four weeks post injection.\nA maximum number of 3 re-injections can be applied."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed as an exploratory study to assess safety and efficacy of two\n      different doses of the anti-VEGF agent ranibizumab (0.12 mg vs. 0.20 mg) in the treatment of\n      infants with retinopathy of prematurity. Furthermore it shall help to improve safety in the\n      treatment of ROP and provide explorative data on long-term effects of ranibizumab after\n      intravitreal injection in neonates.\n\n      The primary objective is to assess clinical efficacy of ranibizumab in children with ROP"
        }, 
        "brief_title": "Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity", 
        "completion_date": {
            "#text": "December 2021", 
            "@type": "Anticipated"
        }, 
        "condition": "Retinopathy of Prematurity (ROP)", 
        "condition_browse": {
            "mesh_term": [
                "Retinal Diseases", 
                "Retinopathy of Prematurity"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Bilateral ROP in zone I (stage 1+, 2+, 3+/-, AP-ROP) or ROP in central (=posterior)\n             zone II (stage 3+, AP-ROP). Zone I is defined as twice the distance from the optic\n             disc to the fovea measured temporally, posterior zone II is defined as three times\n             the distance from the optic disc to the fovea measured temporally.\n\n          -  Legal representatives or their designates willing and able to attend regular study\n             visits with the study infant.\n\n          -  Written informed consent to participate in the study (signed by all patient's legal\n             representatives).\n\n        Exclusion Criteria:\n\n          -  Pediatric conditions rendering the infant ineligible to anti-VEGF treatment or to\n             repeated blood draws as evaluated by a neonatal ICU specialist and a study\n             ophthalmologist.\n\n          -  Congenital brain lesions significantly impairing optic nerve function.\n\n          -  Severe hydrocephalus with significantly increased intracranial pressure.\n\n          -  Advanced stages of ROP with partial or complete retinal detachment (ROP stage 4 and\n             5).\n\n          -  ROP involving only the peripheral retina (i.e. peripheral zone II or zone III).\n\n          -  Known hypersensitivity to the study drug or to drugs with similar chemical\n             structures.\n\n          -  Contraindications for an intravitreal injection as listed in ranibizumab SmPC.\n\n          -  Systemic use of anti-VEGF therapeutics.\n\n          -  Use of other investigational drugs - excluding vitamins and minerals - at the time of\n             enrollment, or within 30 days or 5 half-lives prior to enrollment, whichever is\n             longer."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02134457", 
            "org_study_id": "CARE-ROP", 
            "secondary_id": "2013-002539-13"
        }, 
        "intervention": {
            "arm_group_label": [
                "Ranibizumab 0.12 mg", 
                "Ranibizumab 0.20 mg"
            ], 
            "intervention_name": "ranibizumab", 
            "intervention_type": "Biological", 
            "other_name": "Lucentis"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 6, 2014", 
        "location": [
            {
                "contact": {
                    "email": "andreas.stahl@uniklinik-freiburg.de", 
                    "last_name": "Andreas Stahl, MD", 
                    "phone": "004976127040010"
                }, 
                "contact_backup": {
                    "email": "wolf.lagreze@uniklinik-freiburg.de", 
                    "last_name": "Wolf A Lagr\u00e8ze, MD", 
                    "phone": "004976127040110"
                }, 
                "facility": {
                    "address": {
                        "city": "Freiburg", 
                        "country": "Germany", 
                        "state": "Baden-Wuerttemberg", 
                        "zip": "79106"
                    }, 
                    "name": "University Eye Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Tim U. Krohne, MD"
                }, 
                "contact_backup": {
                    "last_name": "Christian Brinkmann, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Bonn", 
                        "country": "Germany", 
                        "zip": "53127"
                    }, 
                    "name": "University Eye Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Isabel Oberacher-Velten, MD"
                }, 
                "contact_backup": {
                    "last_name": "Horst Helbig, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Regensburg", 
                        "country": "Germany", 
                        "zip": "93053"
                    }, 
                    "name": "University Eye Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Sabine Aisenbrey, MD"
                }, 
                "contact_backup": {
                    "last_name": "Michael Partsch, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Tuebingen", 
                        "country": "Germany", 
                        "zip": "72076"
                    }, 
                    "name": "University Eye Hospital"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multicenter Randomized Double Masked Parallel Design Exploratory Study to Assess Safety and Efficacy of Two Different Doses of Intravitreal Anti-VEGF Treatment With Ranibizumab (0.12 mg vs. 0.20 mg) in Infants With Retinopathy of Prematurity (ROP)", 
        "other_outcome": [
            {
                "measure": "Number of late recurrences of ROP during the follow-up period", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years post first injection"
            }, 
            {
                "measure": "Number of patients progressing to stage 4 or 5 ROP after the core study", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years post first injection"
            }, 
            {
                "measure": "Number of patients with complete vascularization of the peripheral retina to within one disc diameter of the ora serrata after the end of the core study", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years post first injection"
            }, 
            {
                "description": "At one year and at 5 years an ophthalmological visit will take place.", 
                "measure": "Long-term ophthalmological development: visual acuity (if possible), orthoptic status, cycloplegic retinoscopy, refraction, IOP, fundoscopy including fundus photographs", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years post first injection"
            }, 
            {
                "measure": "Long-term pediatric development: Bayley-test, weight, height, cognitive, motor and sensory development", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years post first injection"
            }, 
            {
                "measure": "Number and kind of AEs or SAEs per group between the end of the observational core study and the end of the follow-up period", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 5 years post first injection"
            }
        ], 
        "overall_contact": {
            "email": "andreas.stahl@uniklinik-freiburg.de", 
            "last_name": "Andreas Stahl, MD", 
            "phone": "004976127040010"
        }, 
        "overall_contact_backup": {
            "email": "wolf.lagreze@uniklinik-freiburg.de", 
            "last_name": "Wolf A Lagr\u00e8ze, MD", 
            "phone": "004976127040110"
        }, 
        "overall_official": {
            "affiliation": "University Eye Hospital Freiburg, Germany", 
            "last_name": "Andreas Stahl, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Paul-Ehrlich-Institut", 
                "Germany: Ethics Commission"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Efficacy is determined by the number of infants without need for rescue treatment up to week 24 post first injection.\nRe-injection of study dose is not considered rescue treatment if applied after an initial response to treatment and after at least 4 weeks post injection.", 
            "measure": "Efficacy of treatment", 
            "safety_issue": "No", 
            "time_frame": "Up to 24 weeks post first injection"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02134457"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Hospital Freiburg", 
            "investigator_full_name": "Andreas Stahl, MD", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Regression of plus disease", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 weeks post first injection"
            }, 
            {
                "measure": "Regression of preretinal vascularized ridge", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 weeks post first injection"
            }, 
            {
                "measure": "Progression of peripheral intraretinal vascularization beyond ridge", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 weeks post first injection"
            }, 
            {
                "measure": "Number and kind of AEs and SAEs", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 weeks post first injection"
            }, 
            {
                "measure": "Changes in vascular endothelial growth factor (VEGF) levels in the systemic circulation", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 weeks post first injection"
            }, 
            {
                "measure": "Number of re-injections of study dose", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 weeks post first injection"
            }, 
            {
                "measure": "Number of patients progressing to stage 4 or 5 ROP", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 weeks post first injection"
            }, 
            {
                "measure": "Number of patients with complete vascularization of the peripheral retina to within one disc diameter of the ora serrata", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 weeks post first injection"
            }
        ], 
        "source": "University Hospital Freiburg", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital Freiburg", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}